Tata Medical Center
12
2
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Measuring Ultrasound Guided Skeletal Muscle Mass of Lower Extremity as a Predictor of Post-Operative Length of Stay in Exploratory Gynae-oncology Surgeries
Role: lead
Prostate Radiotherapy Comparing Moderate and Extreme Hypo-fractionation (PRIME Trial)
Role: collaborator
R21 India Pal-Care Evaluation
Role: collaborator
One Week Versus Three Week in Adjuvant Radiotherapy in Breast Cancer
Role: lead
Trial Comparing Avg. Global Qual of Lifescore in Hypo Frac. RT vs Conv. Frac. in H&N Cancers
Role: lead
Dose Escalation Versus Standard in Laryngopharyngeal Cancers
Role: lead
Hypo-Fractionated Radiotherapy in Breast Cancer
Role: lead
Short Course Radiotherapy for Localized Prostate Cancer
Role: lead
Patient Reported Scale vs CTCAE Grading: A Prospective Comparator Study
Role: lead
Comprehensive Digital Archive of Cancer Imaging-Radiation Oncology( CHAVI-RO )
Role: lead
Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer
Role: lead
Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery
Role: lead
All 12 trials loaded